FDA gives AstraZeneca extension on cancer drug application

The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Both companies said they would continue to work with the FDA to facilitate the completion of the agency’s review.